Table 5.

Summary of Changes in Vital Sign Measurements

Placebo (n = 83)Atomoxetine (mg/kg/day)
0.5
n (%)
[95% CI]
(n = 43)
1.2
n(%)
[95% CI]
(n = 84)
1.8
n (%)
[95% CI]
(n = 81)
Blood pressure
 Systolic2.1 (9.5)3.3 (10.4)4.3 (10.4)2.5 (8.8)
[−2.3, 4.9][−0.8, 5.2][−2.6, 3.4]
 Diastolic−1.4 (9.8)1.5 (9.5)2.8 (9.1)*1.7 (10.5)*,
[−0.7, 6.5][1.2, 7.2][0.1, 6.1]
Pulse (bpm)1.6 (10.5)5.8 (9.6)*6.3 (11.9)*8.3 (11.6)*,
[0.1, 8.3][1.3, 8.1][3.3, 10.1]
Weight (kg)1.7 (1.6)0.3 (1.1)*−0.4 (1.4)*−0.5 (1.7)*,
[−2.0, −0.9][−2.6, −1.6][−2.6, −1.7]
  • BPM indicates beats per minute; n, number of patients with a baseline and at least 1 postbaseline vital sign measurement.

  • *P < .05, pairwise comparison with placebo.

  • P < .05, linear dose-response term.

  •  Values reported are mean (SD) change from baseline to endpoint and 95% confidence intervals on treatment difference in mean change scores (atomoxetine-placebo).